Cure Pharmaceutical Holding Corporation Kur Revening in the third quarter increased 32.1% Year-to-date and 58.9% sequentially from Q2 2022 $1.8 million,
Q3 2022 Financial Highlights
Gross profit was $1.4 million compared to $914,000 in Q3 2021.
Gross profit The forecast for the third quarter in 2021 improved by 123 basis points to 80.0% compared to the same period in 2022.
net loss was $3.6 million compared to $4.3 million in Q3 2021.
Cure completed the non-dilutive capital sale of a portion of its platform technology intellectual property portfolio and related assets in July 2022 for total consideration of $20 million. The company retained its 15 patents and will continue to be an incubator for future technologies and patents, which it seeks to monetize through product development or commercialization of technologies through licensing or sales of technologies.
Cure’s wholly owned subsidiary, The Cera Labs, has begun selling six SKUs of its Ceratopical Revolution skincare line with a P3P, proprietary distribution system, in 1,372 Walmart stores as well as on Amazon.com.
Sera Labs has also secured placement for its oral thin film strip, Nutri-Strips, on shelves at CVS, Amazon.com and target.com. Nutri-Strips are owned by Cera Labs and are the result of years of research.
Board of Directors and Governance Update
In August the company appointed gerald bugg And Robert J. Costantino Its board of directors has also been appointed and Costantino as the chairman of Cure’s audit committee. Former Cure CEO Rob Davidson Was appointed as the chairman of the board of directors.
Get your daily dose of cannabis news Benzinga on Cannabis. Don’t miss out on any important developments in the industry.
Photo by Mackenzie Marco on Unsplash
Cure Pharmaceutical Q2 2021 Revenue Spikes 700% After Sales of Serra Labs Products Increase, Including CVS Deal
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga Cannabis Convention
Meet the biggest players in the cannabis industry and make deals that will drive the industry forward.
Featuring live company presentations, insider panels and unrivaled access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet.
Join us on April 11-12, 2023 at Fontainebleau Miami Beach in sunny Florida.